Company Introduction

Founded in December 2012, Junshi Biosciences is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapeutics. It is our company’s spirit that drives us forward.

We have established a globally integrated R&D process. With four R&D centers worldwide, we have the outstanding ability to discover and develop innovative biologics. We are able to independently perform crucial procedures, i.e. target assessments, mechanism studies and validation, clinical drug screening and functional validation, etc.

We have established a diversified R&D pipeline comprising 50+ innovative drug candidates with five therapeutic focuses including cancer, autoimmune disease, metabolic disease, neurological disease, and infectious disease. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA antibody for tumors has been agreed to enter global Phase Ⅲ stage by the FDA and NMPA, and its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA. Our mission is to provide patients with world-class, trustworthy, affordable, and innovative drugs.

We have two monoclonal antibody production bases in China with a combined fermentation capacity of 46,500L, undertaking the manufacturing of both investigational and commercial products.